1. Home
  2. ALTI vs MNPR Comparison

ALTI vs MNPR Comparison

Compare ALTI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$3.77

Market Cap

407.2M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$57.91

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
MNPR
Founded
2020
2014
Country
United States
United States
Employees
490
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.2M
368.9M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ALTI
MNPR
Price
$3.77
$57.91
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$107.00
AVG Volume (30 Days)
143.6K
174.1K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
41.11
54.99
EPS
N/A
N/A
Revenue
$254,956,000.00
N/A
Revenue This Year
$18.06
N/A
Revenue Next Year
$10.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.96
$28.40
52 Week High
$5.45
$105.00

Technical Indicators

Market Signals
Indicator
ALTI
MNPR
Relative Strength Index (RSI) 48.12 52.60
Support Level $3.76 $56.15
Resistance Level $3.95 $60.87
Average True Range (ATR) 0.21 3.81
MACD 0.05 0.40
Stochastic Oscillator 70.00 73.05

Price Performance

Historical Comparison
ALTI
MNPR

About ALTI AlTi Global Inc.

AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: